Kura Oncology, Inc. will present updated Phase 1a results from the ongoing FIT-001 Phase 1a/1b clinical trial evaluating darlifarnib in combination with cabozantinib in advanced renal cell carcinoma (RCC) at the 2026 Kidney Cancer Research Summit (KCRS) in Boston. The presentation will feature long-term follow-up results in heavily pretreated cabozantinib-naïve patients with refractory RCC, providing further evidence of darlifarnib’s potential as a combination agent with VEGFR-targeted therapies. RCC is the most common form of kidney cancer, with clear cell RCC (ccRCC) accounting for more than 61,000 new cases in the U.S. annually.

The FIT-001 trial (NCT06026410) is a Phase 1a/1b study assessing the safety and efficacy of darlifarnib plus cabozantinib in advanced RCC. The updated Phase 1a data is expected to support darlifarnib’s potential to enhance VEGFR-targeted therapy in ccRCC. A global randomized Phase 1b study comparing darlifarnib plus cabozantinib versus cabozantinib alone is currently ongoing.

Key Trial Details

The results continue to support darlifarnib as a precision combination agent across multiple targeted therapy classes. Kura Oncology has scheduled a virtual investor call on July 27, 2026, at 5:00 a.m. PT / 8:00 a.m. ET to discuss the updated data.

Kura Oncology granted inducement awards consisting of nonstatutory stock options to purchase 68,750 shares of common stock to five new employees on July 1, 2026. The grants were approved by the Compensation Committee of the Company’s Board of Directors under the Company’s 2023 Inducement Option Plan, as amended, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards were approved as an inducement material to the employees’ employment.

Each stock option has an exercise price of $10.78 per share, which equals the closing price of the Company’s common stock on July 1, 2026. The options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date. The remaining shares will vest monthly over the subsequent 36 months, subject to the new employees’ continued service relationship with Kura Oncology through the applicable vesting dates.

The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms of an applicable stock option agreement covering the grant. Kura Oncology is a biopharmaceutical company focused on precision medicines for the treatment of cancer.

Grant Details